Literature DB >> 30578336

The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.

Amy L Olson1, Alex H Gifford2, Naohiko Inase3, Evans R Fernández Pérez1, Takafumi Suda4.   

Abstract

The availability of epidemiological data relating to interstitial lung diseases (ILDs) has increased over recent years, but information on the prevalence and incidence of ILDs of different aetiologies remains limited. Despite global distribution, the proportion of patients who develop a progressive phenotype across different ILDs is not well known. Disease behaviour is well documented in idiopathic pulmonary fibrosis but idiosyncratic in other ILDs that may present a progressive fibrosing phenotype. Possible reasons may include the heterogeneous nature of the aetiology, the complexity of diagnosis (and subsequent documentation of cases) and the methods employed to retrospectively analyse patient databases. This review presents a broad overview of the epidemiological data available for ILDs that may present a progressive-fibrosing phenotype, collectively and stratified according to clinical classification. We also note where further data are needed in comparison to the well-studied IPF indication.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 30578336     DOI: 10.1183/16000617.0077-2018

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  37 in total

1.  Serelaxin and the AT2 Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to Candesartan Cilexetil.

Authors:  Yan Wang; Lei Han; Matthew Shen; Emma S Jones; Iresha Spizzo; Sarah L Walton; Kate M Denton; Tracey A Gaspari; Chrishan S Samuel; Robert E Widdop
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-23

2.  Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis.

Authors:  Joshua K Park; Nathan J Coffey; Steven P Bodine; Charles N Zawatsky; Lindsey Jay; William A Gahl; George Kunos; Bernadette R Gochuico; May Christine V Malicdan; Resat Cinar
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

3.  The Diagnosis and Treatment of Pulmonary Fibrosis.

Authors:  Michael Kreuter; Ulf Müller Ladner; Ulrich Costabel; Danny Jonigk; Claus Peter Heussel
Journal:  Dtsch Arztebl Int       Date:  2021-03-05       Impact factor: 5.594

4.  Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study.

Authors:  Yuanying Wang; Ziyun Guo; Ruimin Ma; Jingwei Wang; Na Wu; Yali Fan; Qiao Ye
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

5.  Catalpol Attenuates Pulmonary Fibrosis by Inhibiting Ang II/AT1 and TGF-β/Smad-Mediated Epithelial Mesenchymal Transition.

Authors:  Qun Yu; Dewei Zhu; Yang Zou; Kai Wang; Peili Rao; Yunhui Shen
Journal:  Front Med (Lausanne)       Date:  2022-05-24

6.  Nogo-B promotes epithelial-mesenchymal transition in lung fibrosis via PERK branch of the endoplasmic reticulum stress pathway.

Authors:  Ying Zhu; Meng Yang; Xue-Hui Li; Wu-Jian Xu; Wei Gao; Yu-Han Chen; Jian-Dong Li; Qiang Li
Journal:  Ann Transl Med       Date:  2021-04

7.  The burden of progressive fibrotic interstitial lung disease across the UK.

Authors:  Thomas Simpson; Shaney L Barratt; Paul Beirne; Nazia Chaudhuri; Anjali Crawshaw; Louise E Crowley; Sophie Fletcher; Michael A Gibbons; Philippa Hallchurch; Laura Horgan; Ieva Jakaityte; Thomas Lewis; Tom McLellan; Katherine J Myall; Ryan Miller; David J F Smith; Stefan Stanel; Muhunthan Thillai; Fiona Thompson; Timothy Wallis; Zhe Wu; Philip L Molyneaux; Alex G West
Journal:  Eur Respir J       Date:  2021-07-08       Impact factor: 16.671

Review 8.  Acute exacerbation of interstitial lung disease associated with rheumatic disease.

Authors:  Fabrizio Luppi; Marco Sebastiani; Carlo Salvarani; Elisabeth Bendstrup; Andreina Manfredi
Journal:  Nat Rev Rheumatol       Date:  2021-12-07       Impact factor: 20.543

9.  Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.

Authors:  David Singer; Lindsay G S Bengtson; Craig S Conoscenti; Marianne Laouri; Sharash S Shetty; Amy J Anderson; Kevin K Brown
Journal:  Ann Am Thorac Soc       Date:  2022-07

Review 10.  Cooperative signaling between integrins and growth factor receptors in fibrosis.

Authors:  Horacio Maldonado; James S Hagood
Journal:  J Mol Med (Berl)       Date:  2021-01-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.